TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists

@article{Williams2011TNFAA,
  title={TNF alpha antagonist‐induced lupus‐like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists},
  author={Victoria L. Williams and Philip R. Cohen},
  journal={International Journal of Dermatology},
  year={2011},
  volume={50}
}
Background  In patients with various autoimmune and rheumatic diseases, a drug‐induced lupus‐like syndrome (DILS) has been reported with the use of adalimumab, cerrolizumab pegol, etanercept, and infliximab. 
View on Wiley
ncbi.nlm.nih.gov
130 Citations
Highly Influential Citations
3
Background Citations
29
Results Citations
2

130 Citations

Citation Type

Citation Type

A case of lupus‐like syndrome in a patient receiving adalimumab and a brief review of the literature on drug‐induced lupus erythematosus
TLDR
Anti‐TNF therapies have been found to be associated with a lupus‐like syndrome, which is clinically distinct from classical drug‐induced as well as idiopathic l upus erythematosus. Expand
Lupus-like Syndrome Induced by Anti-tumor Necrosis Factor Treatment
Anti-tumor necrosis factor (TNF) agents have been successfully used in the treatment of inflammatory rheumatic diseases for more than 10 years. Although it is rare disease, a lupus-like syndrome may… Expand
Mechanisms of Tumor Necrosis Factor α Antagonist–Induced Lupus in a Murine Model
TLDR
The role of TNFα in a murine model of lupus was investigated to investigate the use of the molecule in the treatment of rheumatoid arthritis and other inflammatory diseases. Expand
Management Decisions for Rheumatoid Arthritis After Tumor Necrosis Factor Alpha Antagonist-Induced Lupus-Like Syndrome.
TLDR
The management of rheumatoid arthritis patients who develop TAILs and the safety of re-challenging these patients with other biologic therapies remain largely unknown and understudied. Expand
Subacute cutaneous lupus erythematosus and its association with drugs: a population‐based matched case–control study of 234 patients in Sweden
Background  Numerous case reports about drug‐induced (DI) subacute cutaneous lupus erythematosus (SCLE) have been published. Various drug types with different latencies has been proposed as triggers… Expand
TNF-inhibitor induced lupus in a patient treated with adalimumab for rheumatoid arthritis.
TLDR
A case of anti-tumor necrosis factor induced lupus is presented in a patient treated for rheumatoid arthritis (RA) with adalimumab and treatment was started, leading to improvement in the patient's status. Expand
Thromboembolic event associated with antitumor necrosis factor‐alpha treatment: report of a case
TLDR
An unusual case of TE related to anti-TNF-a (infliximab) is presented and it is suggested that TNF- a antagonists induce autoantibodies in predisposed patients. Expand
Anti-tumor necrosis factor-α induced systemic lupus erythematosus in a patient with metastatic Crohn's disease--what is the role of anti-TNF antibody?
TLDR
A case of a 27-year old woman presenting with drug induced systemic lupus erythematosus associated with infliximab therapy is reported, suggesting that in this case a cross reactivity between anti-infliximab antibodies and autoantibodies may lead to the development of TNF-induced immune disease. Expand
Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases
TLDR
To analyze the incidence rate (IR) and risk factors of cutaneous adverse events (CAE) in patients with chronic inflammatory rheumatic diseases treated with tumor necrosis factor (TNF) antagonists, a large number of patients with these diseases are treated with TNF antagonists. Expand
Tumour necrosis factor antagonist‐induced lupus: a Critically Appraised Topic
TLDR
TNF antagonist induced lupus appears to have a good prognosis and treatment should be tailored to each individual case, as cutaneous features are the most common manifestation, it is important that dermatologists are aware of the ACR diagnostic criteria of l upus to ensure accurate diagnoses. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Is the development of drug-related lupus a contraindication for switching from one TNF alpha inhibitor to another?
TLDR
A case of a patient who developed DRL while receiving infliximab therapy which resolved spontaneously upon discontinuation of the agent and did not recur with subsequent institution of adalimumab is described. Expand
Etanercept-induced lupus erythematosus presenting as a unilateral pleural effusion.
TLDR
The spectrum of autoimmune disease due to the use of tumor necrosis factor inhibitors is reviewed and a 72-year-old man receiving etanercept for the treatment of psoriatic arthritis had an exudative pleural effusion. Expand
Etanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid Arthritis
TLDR
This case is to the authors' knowledge, the first report of etanercept-induced SLE in Korea and describes a 55-yr-old Korean woman who developed overt life threatening SLE complicated by pneumonia and tuberculosis following etanenercept treatment for RA. Expand
Unusual toxicities with TNF inhibition: heart failure and drug-induced lupus.
  • J. Cush
  • Medicine
  • Clinical and experimental rheumatology
  • 2004
TLDR
Patients receiving TNF inhibitor therapy have great benefit from anti-TNF therapies, but their intelligent use requires a firm understanding of these rare toxicities, so as to minimize the morbidity associated with their uncommon occurrence. Expand
Autoimmunity and Anti‐TNF‐α Agents
TLDR
Treatment of rheumatoid arthritis patients with anti‐tumor necrosis factor‐alpha (anti‐TNF‐α) biologic agents has been associated with a reduction in the levels of specific autoantibodies, and the induction of non‐ organ‐specific autoantIBodies (antinuclear antibodies [ANAs], anti‐dsDNA, and antiphospholipid antibodies [aPLs). Expand
Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey
TLDR
It appears that no drug was more implicated than the other in lupus syndromes, whose incidence was 15/7700 = 0.19% with infliximab and 7/3800 =0.18% with etanercept. Expand
Anti-TNF-induced lupus.
TLDR
Concomitant immunosuppression can reduce autoantibody formation in ATIL, and withdrawal of anti-TNF-alpha therapy usually leads to resolution of symptoms, and Steroids and/or immunOSuppressive therapy may be required in severe cases. Expand
Drug-Induced Lupus due to Anti-Tumor Necrosis Factor α Agents
TLDR
TNFα DILE has significant clinical and laboratory manifestations which distinguish it from DILE due to drugs other than anti-TNF agents and may be difficult to diagnose in patients treated for autoimmune diseases. Expand
Drug-induced lupus due to anti-tumor necrosis factor alpha agents.
TLDR
TNFalpha DILE has significant clinical and laboratory manifestations which distinguish it from DILE due to drugs other than anti-TNF agents and may be difficult to diagnose in patients treated for autoimmune diseases. Expand
Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
TLDR
The biology of T NF and related family members are discussed in the context of the potential mechanisms of action of TNF antagonists in a variety of immune-mediated inflammatory diseases. Expand
...
1
2
3
4
5
...